Clinical Trial Update: A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer [NA]

View source ↗

Summary

A single-center dose-escalation trial is evaluating the safety, tolerability, and preliminary efficacy of YS247, a tumor neoantigen-pulsed autologous dendritic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer

Drugs mentioned

• YS247

Snippet

Sponsor: Peking University Third Hospital | Conditions: HRD-negative Epithelial Ovarian Cancer | NA | Status: NOT_YET_RECRUITING